Can Respir J. 2013 Sep-Oct;20(5):367-8. doi: 10.1155/2013/506383.
Historically, all non-small cell lung cancers were essentially grouped together and considered to be a single disease. However, it is now recognized that non-small cell lung cancer actually comprises a genetically diverse group of tumours. This, in turn, affords a new opportunity for the development of effective treatments tailored to individual tumours and patients. Advances in molecular biology have made possible the development of drugs against specific molecular targets on cancer cells, most notably the tyrosine kinase inhibitors. The relevant literature and current practice guidelines are discussed. In addition, other related areas of active investigation, including tumour vaccines and pharmacogenetics, are briefly reviewed.
从历史上看，所有非小细胞肺癌基本上都被归为一组，被视为一种单一疾病。然而，现在人们已经认识到，非小细胞肺癌实际上包含了一组具有遗传多样性的肿瘤。这反过来又为开发针对个体肿瘤和患者的有效治疗方法提供了新的机会。分子生物学的进步使得针对癌细胞上特定分子靶点的药物的开发成为可能，其中最著名的是酪氨酸激酶抑制剂。讨论了相关的文献和当前的实践指南。此外，还简要回顾了其他相关的研究领域，包括肿瘤疫苗和药物遗传学。
